0001193125-19-037999.txt : 20190213 0001193125-19-037999.hdr.sgml : 20190213 20190213161702 ACCESSION NUMBER: 0001193125-19-037999 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190213 DATE AS OF CHANGE: 20190213 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Coherus BioSciences, Inc. CENTRAL INDEX KEY: 0001512762 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273615821 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88402 FILM NUMBER: 19597367 BUSINESS ADDRESS: STREET 1: C/O DENNIS M. LANFEAR STREET 2: 333 TWIN DOLPHIN DR, SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 649-3530 MAIL ADDRESS: STREET 1: C/O DENNIS M. LANFEAR STREET 2: 333 TWIN DOLPHIN DR, SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: BioGenerics, Inc. DATE OF NAME CHANGE: 20110210 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Daiichi Sankyo Company, LTD CENTRAL INDEX KEY: 0001340156 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: M0 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 5-1, NIHONBASHI 3-CHOME STREET 2: CHUO-KU, CITY: TOKYO STATE: M0 ZIP: 103-8426 BUSINESS PHONE: (011) 81-3-5255-7041 MAIL ADDRESS: STREET 1: 5-1, NIHONBASHI 3-CHOME STREET 2: CHUO-KU, CITY: TOKYO STATE: M0 ZIP: 103-8426 SC 13G/A 1 d678646dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

COHERUS BIOSCIENCES INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

19249H103

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

13G

 

CUSIP No. 19249H103

    Page 2 of 5 Pages

 

  1.   

Name of reporting persons:

 

Daiichi Sankyo Company, Limited

  2.   

Check the appropriate box if a member of a group

(a)   ☐         (b)   ☐

 

  3.   

SEC use only

 

  4.   

Citizenship or place of organization:

 

Japan

Number of

shares

beneficially

owned by

each

reporting

person

with

    5.    

Sole voting power:

 

0

   6.   

Shared voting power:

 

0

   7.   

Sole dispositive power:

 

0

   8.   

Shared dispositive power:

 

0

  9.  

Aggregate amount beneficially owned by each reporting person:

 

0

10.  

Check box if the aggregate amount in Row (9) excludes certain shares (see instructions) ☐

 

11.  

Percent of class represented by amount in Row (9):

 

0%

12.  

Type of reporting person (see instructions):

 

CO

 

 

Page 2

Item 1.(a).

Name of Issuer

Coherus BioSciences, Inc. (the “Company”)

(b). Address of Issuer’s Principal Executive Offices:

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

 

Item 2(a).

Name of Person Filing

Daiichi Sankyo Company, Limited

 

Item 2(b).

Address of Principal Business Office

The principal business office is:

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan

 

Item 2(c).

Citizenship

Daiichi Sankyo Company, Limited is a Japanese corporation.

 

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.0001 per share (the “Common Stock”)

 

Item 2(e).

CUSIP Number:

19249H103

 

Item 3.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

 

Item 4.

Ownership.

(a) Amount beneficially owned:

As of December 31, 2018, Daiichi Sankyo Company, Limited beneficially owns 0 shares of Common Stock of the Company.

(b) Percent of class:

0%

 

Page 3

(c) Number of Shares as to which the Reporting Person has:

(i) Sole power to vote or to direct the vote:

0.

(ii) Shared power to vote or to direct the vote:

0.

(iii) Sole power to dispose or to direct the disposition of:

0.

(iv) Shared power to dispose or to direct the disposition of:

0.

 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ☒

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

Not Applicable.

 

Item 10.

Certification.

Not Applicable.

 

Page 4

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2019

 

DAIICHI SANKYO COMPANY, LIMITED
  By:   /s/ Kentaro Takamura
  Name:   Kentaro Takamura
  Title:  

Executive Officer

Vice President, Finance & Accounting

 

Page 5